Sandoz has obtained approval from the European Commission for Afqlir® (aflibercept), enhancing its prominent biosimilar lineup.

This opinion endorses the approval of the amyloid-beta (Aβ) monoclonal antibody lecanemab for adult patients diagnosed with mild cognitive impairment and mild dementia due to Alzheimer's disease.

Spirovant Sciences has administered the first dose to a patient in the SAAVe Phase 1/2 trial for its experimental aerosol-based genetic treatment for cystic fibrosis.

Kyverna Therapeutics Reveals Patient Data Showcasing KYV-101's Promise for Lupus Nephritis Treatment at ACR Convergence 2024 Symposium.

Soligenix disclosed that it has commenced the enrollment of patients for its Phase 2 trial (protocol number DUS-AUBD-01) investigating SGX945 (dusquetide).

Merck obtains exclusive global rights for LM-299, a clinical investigational bispecific antibody targeting PD-1 and VEGF, from LaNova Medicines Ltd.

Tune Therapeutics Enters Clinical Arena with TUNE-401: A Novel Epigenetic Silencer Targeting Hepatitis B.

Tirzepatide treatment in obese or overweight adults with pre-diabetes led to lasting weight reduction, with almost 99% staying free of diabetes after 176 weeks.

MoonLake Immunotherapeutics has launched Phase 3 of the IZAR program for the Nanobody® sonelokimab in individuals suffering from active psoriatic arthritis.

Gan & Lee Pharmaceuticals reported favorable Phase 1 outcomes for its oral GLP-1 receptor agonist, GZR18 tablet, in healthy subjects, showing a weight loss of 4.16% over two weeks.

Pimicotinib meaningfully enhanced results for patients with tenosynovial giant cell tumor in an international Phase III study.

New BLA for Datopotamab Deruxtecan filed in the U.S. for fast-track approval in patients with advanced EGFR-mutated non-small cell lung cancer who have received prior treatment.